![]() |
|||||||||||||||||||||||
![]() |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Venor®Mp & Venor®Mp-QP - PCR Detection KitsKIT FOR IN VITRO DIAGNOSIS OF MYCOPLASMA PNEUMONIAE
The Venor®Mp system is an in vitro test for the qualitative and quantitative diagnosis of Mycoplasma pneumoniae in clinical samples. The test is based on the polymerase chain reaction, and thus providing highly sensitive and 100% specific rapid diagnosis. Venor®Mp is CE marked and approved for in vitro clinical diagnostics. The test system has undergone extensive internal validation, as well as external clinical evaluations. Venor®Mp is available as a conventional PCR assay with result evaluation by agarose gel, as well as a quantitative PCR probe system for use on all real-time instruments (Venor®Mp-QP). Ordering
|
![]() Download
Certificate of AnalysisYou will find Your CoA of Your specific lot ins the menu below. [Download available as PDF-file]. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Benefits of Venor®Mp
Test PrincipleThe Venor®Mp Mycoplasma pneumoniae diagnostic kit uses specific primers to amplify a 207 bp nucleotide sequence within the highly conserved and multiple copy P1 cytadhesin gene. Various standard DNA preparation methods can be used for extraction of microbial DNA from respiratory samples followed by Venor®Mp PCR amplification. The amplicon is detected by standard agarose gel electrophoresis. To rule out the presence of PCR inhibitors in the patient specimen, an internal control is included in the kit. When there is no target DNA in the sample, a positive result from the internal control demonstrates that the PCR worked. Quantitative and qualitative PCR assays: We deploy Venor®Mp for the qualitative conventional PCR or Venor®Mp-QP for the quantitative real-time PCR. Venor®Mp-QP is compatible with the LightCycler®, Opticon®, ABI Prism®, SmartCycler®, Mx3000 p® and other devices. BackgroundMycoplasma pneumoniae is a continual source of upper respiratory infections throughout the year and accounts for about 20% of community acquired pneumonias. The spread increases within closed populations to 80%. The incidence of infection is greatest in older children, adolescents, and young adults. The initial presenting symptoms of M. pneumoniae infection after a 2-3 week incubation period may include cough, fever, malaise, chills, sore throat, and headache. Asymptomatic infections account for about 20% of cases. Mycoplasma pneumoniae infections tend to be more chronic and indistingishable from viral causes and other atypical pathogens on the basis of clinical symptoms alone. Thus, in many clinical settings, accurate and rapid diagnosis is important for an efficient patient management. Diagnosis of acute infections is usually based on culture and serology, known to be difficult by means of insensitivity, delayed detection, and poor specificity. Venor®Mp Mycoplasma pneumoniae diagnostic kit incorporates the highly-sensitive PCR technology and overcomes all drawbacks of these other techniques with its unique features. Kit Components
We highly recommend our reliable hot-start MB Taq DNA Polymerase for extreme sensitive PCR detection of mycoplasma (Cat. No. 53-0200).
Venor®Mp kit components are lyophilized and at +2 bis +8 °C maintainable for at least 12 months. Primer and nucleotides are aliquoted (á 25 tests) to guarantee consistent quality. After rehydratisation the reagents must be stored at -18 °C. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| top |
| Update: 22.07.2008 // Mail: info@minerva-biolabs.com // Contact // Terms and Conditions // Site Map // © 2008 Minerva Biolabs GmbH | |